ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 144 filers reported holding ESPERION THERAPEUTICS INC NE in Q2 2021. The put-call ratio across all filers is 2.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,295,578 | -38.2% | 11,526,100 | -12.3% | 0.07% | -36.0% |
| Q2 2023 | $18,263,983 | -14.0% | 13,139,556 | -1.6% | 0.11% | -15.9% |
| Q1 2023 | $21,233,156 | -50.2% | 13,354,186 | +95.0% | 0.13% | -54.0% |
| Q4 2022 | $42,665,395 | -14.7% | 6,848,378 | -8.2% | 0.29% | -17.3% |
| Q3 2022 | $50,002,000 | +4.2% | 7,463,016 | -1.1% | 0.35% | +14.5% |
| Q2 2022 | $47,993,000 | +27.0% | 7,546,008 | -7.4% | 0.30% | +62.9% |
| Q1 2022 | $37,804,000 | +18.4% | 8,147,380 | +27.6% | 0.19% | +43.1% |
| Q4 2021 | $31,931,000 | -19.1% | 6,386,263 | +95.0% | 0.13% | -18.8% |
| Q3 2021 | $39,456,000 | -50.5% | 3,274,360 | -13.1% | 0.16% | -50.5% |
| Q2 2021 | $79,671,000 | -31.0% | 3,766,935 | -8.5% | 0.32% | -37.8% |
| Q1 2021 | $115,512,000 | +11.1% | 4,118,085 | +3.0% | 0.52% | +1.4% |
| Q4 2020 | $103,949,000 | +16.1% | 3,998,010 | +65.9% | 0.51% | -10.2% |
| Q3 2020 | $89,568,000 | +40.3% | 2,409,683 | +93.6% | 0.57% | +23.4% |
| Q2 2020 | $63,851,000 | +123.4% | 1,244,426 | +37.3% | 0.46% | +55.0% |
| Q1 2020 | $28,577,000 | -27.9% | 906,336 | +36.4% | 0.30% | -8.3% |
| Q4 2019 | $39,636,000 | +71.5% | 664,707 | +5.4% | 0.32% | +47.7% |
| Q3 2019 | $23,110,000 | -22.2% | 630,397 | -1.2% | 0.22% | -23.9% |
| Q2 2019 | $29,697,000 | +16.0% | 638,375 | +0.1% | 0.29% | +3.6% |
| Q1 2019 | $25,607,000 | -1.1% | 637,789 | +13.4% | 0.28% | -19.1% |
| Q4 2018 | $25,881,000 | +4.7% | 562,624 | +1.0% | 0.34% | +21.9% |
| Q3 2018 | $24,727,000 | +16.6% | 557,285 | +3.0% | 0.28% | +11.0% |
| Q2 2018 | $21,202,000 | -50.4% | 541,012 | -8.5% | 0.26% | -53.9% |
| Q1 2018 | $42,765,000 | -6.3% | 591,242 | -14.7% | 0.55% | -8.6% |
| Q4 2017 | $45,645,000 | +27.7% | 693,265 | -2.8% | 0.60% | +24.7% |
| Q3 2017 | $35,756,000 | +2.2% | 713,404 | -5.6% | 0.48% | -0.6% |
| Q2 2017 | $34,974,000 | +29.2% | 755,715 | -1.4% | 0.49% | +22.3% |
| Q1 2017 | $27,067,000 | +301.7% | 766,543 | +42.4% | 0.40% | +291.2% |
| Q4 2016 | $6,738,000 | -7.6% | 538,194 | +2.2% | 0.10% | -6.4% |
| Q3 2016 | $7,295,000 | +38.3% | 526,717 | -1.3% | 0.11% | +34.6% |
| Q2 2016 | $5,274,000 | -57.9% | 533,774 | -29.7% | 0.08% | -57.6% |
| Q1 2016 | $12,519,000 | -21.4% | 759,183 | +6.1% | 0.19% | -13.2% |
| Q4 2015 | $15,929,000 | -2.2% | 715,581 | +3.7% | 0.22% | +0.9% |
| Q3 2015 | $16,286,000 | -71.7% | 690,373 | -1.8% | 0.22% | -65.2% |
| Q2 2015 | $57,505,000 | -17.8% | 703,333 | -6.9% | 0.63% | -13.6% |
| Q1 2015 | $69,966,000 | +72.5% | 755,571 | -24.6% | 0.73% | +72.4% |
| Q4 2014 | $40,550,000 | +183.9% | 1,002,722 | +71.7% | 0.42% | +180.7% |
| Q3 2014 | $14,285,000 | +49.3% | 584,034 | -3.3% | 0.15% | +61.3% |
| Q2 2014 | $9,568,000 | +4.3% | 604,031 | -0.4% | 0.09% | +4.5% |
| Q1 2014 | $9,171,000 | +7.7% | 606,564 | -2.1% | 0.09% | +6.0% |
| Q4 2013 | $8,516,000 | +4.9% | 619,824 | +44.0% | 0.08% | 0.0% |
| Q3 2013 | $8,115,000 | +36.9% | 430,295 | +2.3% | 0.08% | +29.2% |
| Q2 2013 | $5,928,000 | – | 420,453 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,679,835 | $69,675,000 | 19.39% |
| Endurant Capital Management LP | 207,293 | $5,390,000 | 1.94% |
| Bellevue Group AG | 5,138,451 | $133,599,000 | 1.53% |
| Rhenman & Partners Asset Management AB | 592,225 | $15,398,000 | 1.26% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,562,869 | $40,635,000 | 0.93% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 31,434 | $817,000 | 0.62% |
| WASATCH ADVISORS LP | 3,998,010 | $103,949,000 | 0.51% |
| HAMILTON LANE ADVISORS LLC | 46,181 | $1,201,000 | 0.45% |
| Boxer Capital, LLC | 500,000 | $13,000,000 | 0.42% |
| DCF Advisers, LLC | 38,500 | $1,001,000 | 0.41% |